Abstract
BackgroundMEASURE 1 (NCT01358175) is a randomized, double-blind, placebo (PBO)-controlled trial that has demonstrated the efficacy and safety of secukinumab, a human anti–interleukin-17A monoclonal antibody, in subjects with active ankylosing spondylitis...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have